Search

Your search keyword '"Armstrong, Andrew"' showing total 2,255 results
Start Over Author "Armstrong, Andrew"
2,255 results on '"Armstrong, Andrew"'

1. Heterostructure and Interfacial Engineering for Low-Resistance Contacts to Ultra-Wide Bandgap AlGaN

Author

Zhu, Yinxuan, Allerman, Andrew A., Joishi, Chandan, Pratt, Jonathan, Xavier, Agnes Maneesha Dominic Merwin, Ortiz, Gabriel Calderon, Klein, Brianna A., Armstrong, Andrew, Hwang, Jinwoo, and Rajan, Siddharth

Subjects
Condensed Matter - Materials Science
Abstract

We report on the heterostructure and interfacial engineering of metalorganic chemical vapor deposition (MOCVD) grown reverse-graded contacts to ultra-wide bandgap AlGaN. A record low contact resistivity of 1.4 x 10-6 Ohm.cm2 was reported on an Al0.82Ga0.18N metal semiconductor field effect transistor (MESFET) by compositionally grading the contact layer from Al0.85Ga0.15N to Al0.14Ga0.86N with degenerate doping and proper interfacial engineering considering bandgap-narrowing-induced band offset between channel and contact layer. This represents orders-of-magnitude of lower contact resistivity than that obtained in similar MOCVD-grown structures. A detailed, layer-by-layer analysis of the reverse graded contact and TCAD simulation of the bandgap narrowing effect highlighted that the reverse graded contact layer itself is extremely conductive and interfacial resistance due to bandgap-narrowing-induced barrier between contact and channel dominates the contact resistance.

Published
2024

2. Tunnel Junction-Enabled Monolithically Integrated GaN Micro-Light Emitting Transistor

Author

Rahman, Sheikh Ifatur, Awwad, Mohammad, Joishi, Chandan, Eddine, Zane-Jamal, Gunning, Brendan, Armstrong, Andrew, and Rajan, Siddharth

Subjects
Physics - Applied Physics
Abstract

GaN/InGaN microLEDs are a very promising technology for next generation displays. Switching control transistors and their integration are key components in achieving high-performance, efficient displays. Monolithic integration of microLEDs with GaN switching devices provides an opportunity to control microLED output power with capacitive (voltage) control rather than current controlled schemes. This approach can greatly reduce system complexity for the driver circuit arrays while maintaining device opto-electronic performance. In this work, we demonstrate a 3-terminal GaN micro-light emitting transistor that combines a GaN/InGaN blue tunneling-based microLED with a GaN n-channel FET. The integrated device exhibits excellent gate control, drain current control and optical emission control. This work provides a promising pathway for future monolithic integration of GaN FETs with microLED to enable fast switching high efficiency microLED display and communication systems.

Published
2024

4. Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2.

Author

Bryce, Alan, Crawford, E, Agarwal, Neeraj, Hussain, Maha, Beltran, Himisha, Cooperberg, Matthew, Petrylak, Daniel, Shore, Neal, Spratt, Daniel, Tagawa, Scott, Antonarakis, Emmanuel, Aparicio, Ana, Armstrong, Andrew, Boike, Thomas, Calais, Jeremie, Carducci, Michael, Chapin, Brian, Cookson, Michael, Davis, John, Dorff, Tanya, Eggener, Scott, Feng, Felix, Gleave, Martin, Higano, Celestia, Iagaru, Andrei, Morgans, Alicia, Morris, Michael, Murray, Katie, Poage, Wendy, Rettig, Matthew, Sartor, Oliver, Scher, Howard, Sieber, Paul, Small, Eric, Srinivas, Sandy, Yu, Evan, Zhang, Tian, and Koo, Phillip

Subjects
androgen antagonists, biomarkers, precision medicine, prostatic neoplasms, radiotherapy
Abstract

BACKGROUND: Management strategies for metastatic castration-resistant prostate cancer (mCRPC) have rapidly shifted in recent years. As novel imaging and therapeutic approaches have made their way to the clinic, providers are encountering increasingly challenging clinical scenarios, with limited guidance from the current literature. MATERIALS AND METHODS: The US Prostate Cancer Conference (USPCC) is a multidisciplinary meeting of prostate cancer experts intended to address the many challenges of prostate cancer management. At the first annual USPCC meeting, areas of controversy and consensus were identified during a 2-day meeting that included expert presentations, full-panel discussions, and postdiscussion responses to questions developed by the USPCC cochairs and session moderators. RESULTS: This narrative review covers the USPCC expert discussion and perspectives relevant to mCRPC, including neuroendocrine/aggressive-variant prostate cancer (NEPC/AVPC). Areas of broad agreement identified among USPCC experts include the benefits of poly (ADP-ribose) polymerase (PARP) inhibitors for patients with BRCA1/2 mutations, the use of radioligand therapy in patients with prostate-specific membrane antigen (PSMA)-positive mCRPC, and the need for clinical trials that address real-world clinical questions, including the performance of novel therapies when compared with modern standard-of-care treatment. Ongoing areas of controversy and uncertainty included the appropriateness of PARP inhibitors in patients with non-BRCA1/2 mutations, the optimal definition of PSMA positivity, and systemic therapies for patients with NEPC/AVPC after progression on platinum-based therapies. CONCLUSIONS: The first annual USPCC meeting identified several areas of controversy in the management of mCRPC, highlighting the urgent need for clinical trials designed to facilitate treatment selection and sequencing in this heterogeneous disease state.

Published
2024

5. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1.

Author

Crawford, E, Bryce, Alan, Hussain, Maha, Agarwal, Neeraj, Beltran, Himisha, Cooperberg, Matthew, Petrylak, Daniel, Shore, Neal, Spratt, Daniel, Tagawa, Scott, Antonarakis, Emmanuel, Aparicio, Ana, Armstrong, Andrew, Boike, Thomas, Calais, Jeremie, Carducci, Michael, Chapin, Brian, Cookson, Michael, Davis, John, Dorff, Tanya, Eggener, Scott, Feng, Felix, Gleave, Martin, Higano, Celestia, Iagaru, Andrei, Morgans, Alicia, Morris, Michael, Murray, Katie, Poage, Wendy, Rettig, Matthew, Sartor, Oliver, Scher, Howard, Sieber, Paul, Small, Eric, Srinivas, Sandy, Yu, Evan, Zhang, Tian, and Koo, Phillip

Subjects
biomarkers, ndrogen antagonists, precision medicine, prostatic neoplasms, radiotherapy
Abstract

PURPOSE: Castration-sensitive prostate cancer (CSPC) is a complex and heterogeneous condition encompassing a range of clinical presentations. As new approaches have expanded management options, clinicians are left with myriad questions and controversies regarding the optimal individualized management of CSPC. MATERIALS AND METHODS: The US Prostate Cancer Conference (USPCC) multidisciplinary panel was assembled to address the challenges of prostate cancer management. The first annual USPCC meeting included experts in urology, medical oncology, radiation oncology, and nuclear medicine. USPCC co-chairs and session moderators identified key areas of controversy and uncertainty in prostate cancer management and organized the sessions with multidisciplinary presentations and discussion. Throughout the meeting, experts responded to questions prepared by chairs and moderators to identify areas of agreement and controversy. RESULTS: The USPCC panel discussion and question responses for CSPC-related topics are presented. Key advances in CSPC management endorsed by USPCC experts included the development and clinical utilization of gene expression classifiers and artificial intelligence (AI) models for risk stratification and treatment selection in specific patient populations, the use of advanced imaging modalities in patients with clinically localized unfavorable intermediate or high-risk disease and those with biochemical recurrence, recommendations of doublet or triplet therapy for metastatic CSPC (mCSPC), and consideration of prostate and/or metastasis-directed radiation therapy in select patients with mCSPC. CONCLUSIONS: CSPC is a diverse disease with many therapeutic options and the potential for adverse outcomes associated with either undertreatment or overtreatment. Future studies are needed to validate and clinically integrate novel technologies, including genomics, AI, and advanced imaging, to optimize outcomes among patients with CSPC.

Published
2024

8. Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer.

Author

Spratt, Daniel, Tang, Siyi, Sun, Yilun, Huang, Huei-Chung, Chen, Emmalyn, Mohamad, Osama, Armstrong, Andrew, Tward, Jonathan, Nguyen, Paul, Lang, Joshua, Zhang, Jingbin, Mitani, Akinori, Simko, Jeffry, DeVries, Sandy, van der Wal, Douwe, Pinckaers, Hans, Monson, Jedidiah, Campbell, Holly, Wallace, James, Ferguson, Michelle, Bahary, Jean-Paul, Schaeffer, Edward, Sandler, Howard, Tran, Phuoc, Rodgers, Joseph, Esteva, Andre, Yamashita, Rikiya, and Feng, Felix

Subjects
Male, Humans, Prostatic Neoplasms, Androgen Antagonists, Prostate-Specific Antigen, Artificial Intelligence, Hormones
Abstract

BACKGROUND: Androgen deprivation therapy (ADT) with radiotherapy can benefit patients with localized prostate cancer. However, ADT can negatively impact quality of life, and there remain no validated predictive models to guide its use. METHODS: We used digital pathology images from pretreatment prostate tissue and clinical data from 5727 patients enrolled in five phase 3 randomized trials, in which treatment was radiotherapy with or without ADT, as our data source to develop and validate an artificial intelligence (AI)–derived predictive patient-specific model that would determine which patients would develop the primary end point of distant metastasis. The model used baseline data to provide a binary output that a given patient will likely benefit from ADT or not. After the model was locked, validation was performed using data from NRG Oncology/Radiation Therapy Oncology Group (RTOG) 9408 (n=1594), a trial that randomly assigned men to radiotherapy plus or minus 4 months of ADT. Fine–Gray regression and restricted mean survival times were used to assess the interaction between treatment and the predictive model and within predictive model–positive, i.e., benefited from ADT, and –negative subgroup treatment effects. RESULTS: Overall, in the NRG/RTOG 9408 validation cohort (14.9 years of median follow-up), ADT significantly improved time to distant metastasis. Of these enrolled patients, 543 (34%) were model positive, and ADT significantly reduced the risk of distant metastasis compared with radiotherapy alone. Of 1051 patients who were model negative, ADT did not provide benefit. CONCLUSIONS: Our AI-based predictive model was able to identify patients with a predominantly intermediate risk for prostate cancer likely to benefit from short-term ADT. (Supported by a grant [U10CA180822] from NRG Oncology Statistical and Data Management Center, a grant [UG1CA189867] from NCI Community Oncology Research Program, a grant [U10CA180868] from NRG Oncology Operations, and a grant [U24CA196067] from NRG Specimen Bank from the National Cancer Institute and by Artera, Inc. ClinicalTrials.gov numbers NCT00767286, NCT00002597, NCT00769548, NCT00005044, and NCT00033631.)

Published
2023

12. DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes

Author

Graham, Laura S., Henderson, Nicholas C., Kellezi, Olesia, Hwang, Clara, Barata, Pedro C., Bilen, Mehmet A., Kilari, Deepak, Pierro, Michael, Thapa, Bicky, Tripathi, Abhishek, Mo, George, Labriola, Matthew, Park, Joseph J., Rothstein, Shoshana, Garje, Rohan, Koshkin, Vadim S., Patel, Vaibhav G., Dorff, Tanya, Armstrong, Andrew J., McKay, Rana R., Alva, Ajjai, and Schweizer, Michael T.

Published
2024
Full Text
View/download PDF

16. Revenue patterns of piped water services in rural Africa

Author

Armstrong, Andrew, Hope, Robert, and Koehler, Johanna

Subjects
Human geography--Africa, Water-supply
Abstract

Rural Africa lags behind all other global regions in progress towards establishing universal and equitable access to safely managed drinking water. This challenge is marked by a notional interest in piped water for achieving service level goals while increasing demand and financial viability. Yet, a paucity of reliable information and evidence perpetuates unrealistic assumptions of how infrastructure and payment collection alternatives influence seasonal revenue generation. The emergence of professional service delivery models offers new sources of operational and financial data with potential to address knowledge gaps and inform viable, resilient, and equitable drinking water investments. The primary aim of this project is to understand how seasonal patterns of domestic water use and payments affect revenue from piped water services in rural Africa. Empirical analyses have drawn on longitudinal records from Ghana, Kenya, Malawi, Rwanda, Tanzania, and Uganda that cumulatively span more than 500 service-years. In contrast to conventional assumptions, findings suggest household-level services exhibit similar seasonal revenue variability as off-site services and are not consistently associated with higher revenue when tariff level is controlled. Piped service areas with consistent seasonal rainfall have a third less revenue during wet months. Furthermore, prepaid credit payments do not consistently improve revenue generation compared to conventional payment approaches. Three recommendations for rural water policy and practice are highlighted from this research. First, the threat of seasonal revenue variability to rural piped water services can be characterised by assessing rainfall patterns on localised, intra-seasonal scales. Second, complementary revenue patterns of on- and off-premises services can be leveraged at incremental stages of infrastructure investment. Third, caution should be exercised when considering prepaid credit over conventional payment approaches to prevent unrealistic revenue expectations and perverse outcomes.

Published
2022

19. Gut microbe-targeted choline trimethylamine lyase inhibition improves obesity via rewiring of host circadian rhythms.

Author

Schugar, Rebecca, Gliniak, Christy, Osborn, Lucas, Massey, William, Sangwan, Naseer, Horak, Anthony, Banerjee, Rakhee, Orabi, Danny, Helsley, Robert, Brown, Amanda, Burrows, Amy, Finney, Chelsea, Fung, Kevin, Allen, Frederick, Ferguson, Daniel, Gromovsky, Anthony, Neumann, Chase, Cook, Kendall, McMillan, Amy, Buffa, Jennifer, Anderson, James, Mehrabian, Margarete, Goudarzi, Maryam, Willard, Belinda, Mak, Tytus, Armstrong, Andrew, Swanson, Garth, Keshavarzian, Ali, Garcia-Garcia, Jose, Wang, Zeneng, Lusis, Aldons, Hazen, Stanley, and Brown, Jonathan

Subjects
drug delivery, genetic diseases, gut microbiome, medicine, mouse, nutrition, Animals, Choline, Circadian Rhythm, Diet, High-Fat, Enzyme Inhibitors, Gastrointestinal Microbiome, Leptin, Lyases, Male, Methylamines, Mice, Mice, Inbred C57BL, Obesity
Abstract

Obesity has repeatedly been linked to reorganization of the gut microbiome, yet to this point obesity therapeutics have been targeted exclusively toward the human host. Here, we show that gut microbe-targeted inhibition of the trimethylamine N-oxide (TMAO) pathway protects mice against the metabolic disturbances associated with diet-induced obesity (DIO) or leptin deficiency (Lepob/ob). Small molecule inhibition of the gut microbial enzyme choline TMA-lyase (CutC) does not reduce food intake but is instead associated with alterations in the gut microbiome, improvement in glucose tolerance, and enhanced energy expenditure. We also show that gut microbial CutC inhibition is associated with reorganization of host circadian control of both phosphatidylcholine and energy metabolism. This study underscores the relationship between microbe and host metabolism and provides evidence that gut microbe-derived trimethylamine (TMA) is a key regulator of the host circadian clock. This work also demonstrates that gut microbe-targeted enzyme inhibitors have potential as anti-obesity therapeutics.

Published
2022

20. Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations

Author

Park, Joseph J., Chu, Alec, Li, Jinju, Ali, Alicia, McKay, Rana R., Hwang, Clara, Labriola, Matthew K., Jang, Albert, Kilari, Deepak, Mo, George, Ravindranathan, Deepak, Graham, Laura S., Sokolova, Alexandra, Tripathi, Abhishek, Pilling, Amanda, Jindal, Tanya, Ravindra, Aditya, Cackowski, Frank C., Sweeney, Patrick L., Thapa, Bicky, Amery, Taylor S., Heath, Elisabeth I., Garje, Rohan, Zakharia, Yousef, Koshkin, Vadim S., Bilen, Mehmet A., Schweizer, Michael T., Barata, Pedro C., Dorff, Tanya B., Cieslik, Marcin, Alva, Ajjai S., and Armstrong, Andrew J.

Published
2024
Full Text
View/download PDF

21. A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate CancerPhase Ib Trial of Atezo + Radium-223 in Pts with mCRPC

Author

Fong, Lawrence, Morris, Michael J, Sartor, Oliver, Higano, Celestia S, Pagliaro, Lance, Alva, Ajjai, Appleman, Leonard J, Tan, Winston, Vaishampayan, Ulka, Porcu, Raphaelle, Tayama, Darren, Kadel, Edward E, Yuen, Kobe C, Datye, Asim, Armstrong, Andrew J, and Petrylak, Daniel P

Subjects
Cancer, Clinical Research, Urologic Diseases, Clinical Trials and Supportive Activities, Prostate Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Combined Modality Therapy, Double-Blind Method, Humans, Immune Checkpoint Inhibitors, Male, Middle Aged, Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant, Radium, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeMen with metastatic castration-resistant prostate cancer (mCRPC) have limited treatment options after progressing on hormonal therapy and chemotherapy. Here, we evaluate the safety and efficacy of atezolizumab (anti-PD-L1) + radium-223 dichloride (radium-223) in men with mCRPC.Patients and methodsThis phase Ib study evaluated atezolizumab + radium-223 in men with mCRPC and bone and lymph node and/or visceral metastases that progressed after androgen pathway inhibitor treatment. Following safety assessment of concurrent dosing, 45 men were randomized 1:1:1 to concurrent or one of two staggered dosing schedules with either agent introduced one cycle before the other. This was followed by a safety-efficacy expansion cohort (randomized 1:1:1). The primary endpoints were safety and objective response rate (ORR) by RECIST 1.1. Secondary endpoints included radiographic progression-free survival (rPFS), PSA responses, and overall survival (OS).ResultsAs of October 4, 2019, 44 of 45 men were evaluable. All 44 had ≥1 all-cause adverse event (AE); 23 (52.3%) had a grade 3/4 AE. Fifteen (34.1%) grade 3/4 and 3 (6.8%) grade 5 AEs were related to atezolizumab; none were related to radium-223. Confirmed ORR was 6.8% [95% confidence interval (CI), 1.4-18.7], median rPFS was 3.0 months (95% CI, 2.8-4.6), median PSA progression was 3.0 months (95% CI, 2.8-3.3), and median OS was 16.3 months (95% CI, 10.9-22.3).ConclusionsThis phase Ib study demonstrated that atezolizumab + radium-223, regardless of administration schedule, had greater toxicity than either drug alone, with no clear evidence of additional clinical benefit for patients with mCRPC and bone and lymph node and/or visceral metastases.

Published
2021

22. Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer

Author

Deek, Matthew P., Sutera, Philip, Jing, Yuezhou, Gao, Robert, Rothman, Emily, Day, Heather, Chang, David, Dirix, Piet, Armstrong, Andrew J., Campbell, Bethany, Lopez Campos, Fernando, Berenguer, Miguel, Ramotar, Matthew, Conde-Moreno, Antonio, Berlin, Alejandro, Bosetti, Davide Giovanni, Corcoran, Niall, Koontz, Bridget, Mercier, Carole, Siva, Shankar, Pryor, David, Ost, Piet, Huynh, Mai Anh, Kroeze, Stephanie, Stish, Bradley, Kiess, Ana, Trock, Bruce, Tran, Phuoc T., Gillessen, Silke, and Sweeney, Christopher

Published
2024
Full Text
View/download PDF

23. Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial

Author

Zhang, Tian, Howard, Lauren, Koontz, Bridget F., Tagawa, Scott T., Nagar, Himanshu, Bitting, Rhonda L., Frizzell, Bart A., Nordquist, Luke, Rasmussen, Julia, Riggan, Colleen, Reyes, Marco, Davies, Catrin, Gray, Steven R., Newman, Carly R., Fernandez, Escarleth, Ramalingam, Sundhar, Harrison, Michael R., George, Daniel J., Wu, Yuan, and Armstrong, Andrew J.

Published
2024
Full Text
View/download PDF

26. All-MOCVD-Grown Gallium Nitride Diodes with Ultra-Low Resistance Tunnel Junctions

Author

Hasan, Syed M. N., Gunning, Brendan P., -Eddine, Zane J., Chandrasekar, Hareesh, Crawford, Mary H., Armstrong, Andrew, Rajan, Siddharth, and Arafin, Shamsul

Subjects
Condensed Matter - Materials Science
Abstract

We carefully investigate three important effects including postgrowth activation annealing, delta ({\delta}) dose and p+-GaN layer thickness and experimentally demonstrate their influence on the electrical properties of GaN p-n homojunction diodes with a tunnel junction (TJ)-based p-contact. The p-n diodes and TJ structures were monolithically grown by metalorganic chemical vapor deposition (MOCVD) in a single growth step. By optimizing the annealing time and temperature for magnesium (Mg) activation and introducing {\delta}-doses for both donors and acceptors at TJ interfaces, a significant improvement in electrical properties is achieved. For the continuously-grown, all-MOCVD GaN homojunction TJs, ultra-low forward voltage penalties of 158 mV and 490 mV are obtained at current densities of 20 A/cm2 and 100 A/cm2, respectively. The p-n diode with an engineered TJ shows a record-low normalized differential resistance of 1.6 x 10-4 {\Omega}-cm2 at 5 kA/cm2.

Published
2020

27. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

Author

Saad, Fred, Clarke, Noel W, Oya, Mototsugu, Shore, Neal, Procopio, Giuseppe, Guedes, João Daniel, Arslan, Cagatay, Mehra, Niven, Parnis, Francis, Brown, Emma, Schlürmann, Friederike, Joung, Jae Young, Sugimoto, Mikio, Sartor, Oliver, Liu, Yu-Zhen, Poehlein, Christian, Barker, Laura, del Rosario, Paula Michelle, and Armstrong, Andrew J

Published
2023
Full Text
View/download PDF

29. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES

Author

Armstrong, Andrew J., Iguchi, Taro, Azad, Arun A., Villers, Arnauld, Alekseev, Boris, Petrylak, Daniel P., Szmulewitz, Russell Z., Alcaraz, Antonio, Shore, Neal D., Holzbeierlein, Jeffrey, Gomez-Veiga, Francisco, Rosbrook, Brad, Zohren, Fabian, Haas, Gabriel P., Gourgiotti, Georgia, El-Chaar, Nader, and Stenzl, Arnulf

Published
2023
Full Text
View/download PDF

30. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

Author

Sartor, Oliver, Armstrong, Andrew J, Ahaghotu, Chiledum, McLeod, David G, Cooperberg, Matthew R, Penson, David F, Kantoff, Philip W, Vogelzang, Nicholas J, Hussain, Arif, Pieczonka, Christopher M, Shore, Neal D, Quinn, David I, Small, Eric J, Heath, Elisabeth I, Tutrone, Ronald F, Schellhammer, Paul F, Harmon, Matthew, Chang, Nancy N, Sheikh, Nadeem A, Brown, Bruce, Freedland, Stephen J, and Higano, Celestia S

Subjects
Cancer, Prostate Cancer, Urologic Diseases, Adult, Black or African American, Aged, Aged, 80 and over, Cancer Vaccines, Disease Progression, Follow-Up Studies, Health Status Disparities, Humans, Infusions, Intravenous, Kallikreins, Kaplan-Meier Estimate, Male, Middle Aged, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant, Registries, Time Factors, Tissue Extracts, Treatment Outcome, White People, Oncology and Carcinogenesis, Urology & Nephrology
Abstract

PurposeAfrican Americans experience greater prostate cancer risk and mortality than do Caucasians. An analysis of pooled phase III data suggested differences in overall survival (OS) between African American and Caucasian men receiving sipuleucel-T. We explored this in PROCEED (NCT01306890), an FDA-requested registry in over 1900 patients with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T.Patients and methodsOS for patients who received ≥1 sipuleucel-T infusion was compared between African American and Caucasian men using an all patient set and a baseline prostate-specific antigen (PSA)-matched set (two Caucasians to every one African American with baseline PSAs within 10% of each other). Univariable and multivariable analyses were conducted. Survival data were examined using Kaplan-Meier and Cox proportional hazard methodologies.ResultsMedian follow-up was 46.6 months. Overall survival differed between African American and Caucasian men with hazard ratios (HR) of 0.81 (95% confidence interval [CI]: 0.68-0.97, P = 0.03) in the all patient set and 0.70 (95% CI: 0.57-0.86, P

Published
2020

31. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer

Author

Li, Yanjing, He, Yiping, Butler, William, Xu, Lingfan, Chang, Yan, Lei, Kefeng, Zhang, Hong, Zhou, Yinglu, Gao, Allen C, Zhang, Qingfu, Taylor, Daniel G, Cheng, Donghui, Farber-Katz, Suzette, Karam, Rachid, Landrith, Tyler, Li, Bing, Wu, Sitao, Hsuan, Vickie, Yang, Qing, Hu, Hailiang, Chen, Xufeng, Flowers, Melissa, McCall, Shannon J, Lee, John K, Smith, Bryan A, Park, Jung Wook, Goldstein, Andrew S, Witte, Owen N, Wang, Qianben, Rettig, Matthew B, Armstrong, Andrew J, Cheng, Qing, and Huang, Jiaoti

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Urologic Diseases, Aging, Prostate Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Aetiology, 2.1 Biological and endogenous factors, Animals, Biomarkers, Tumor, Cell Line, Tumor, Cell Membrane, Disease Progression, Drug Resistance, Neoplasm, Humans, Male, Mice, Nude, Molecular Targeted Therapy, Neoplasm Grading, Neoplastic Stem Cells, Neovascularization, Pathologic, Neuroendocrine Tumors, Neurosecretory Systems, Phenotype, Prostatic Neoplasms, Receptors, Interleukin-8B, Signal Transduction, Tumor Microenvironment, Biological Sciences, Medical and Health Sciences, Medical biotechnology, Biomedical engineering
Abstract

Hormonal therapy targeting androgen receptor (AR) is initially effective to treat prostate cancer (PCa), but it eventually fails. It has been hypothesized that cellular heterogeneity of PCa, consisting of AR+ luminal tumor cells and AR- neuroendocrine (NE) tumor cells, may contribute to therapy failure. Here, we describe the successful purification of NE cells from primary fresh human prostate adenocarcinoma based on the cell surface receptor C-X-C motif chemokine receptor 2 (CXCR2). Functional studies revealed CXCR2 to be a driver of the NE phenotype, including loss of AR expression, lineage plasticity, and resistance to hormonal therapy. CXCR2-driven NE cells were critical for the tumor microenvironment by providing a survival niche for the AR+ luminal cells. We demonstrate that the combination of CXCR2 inhibition and AR targeting is an effective treatment strategy in mouse xenograft models. Such a strategy has the potential to overcome therapy resistance caused by tumor cell heterogeneity.

Published
2019

32. Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

Author

Higano, Celestia S, Armstrong, Andrew J, Sartor, A Oliver, Vogelzang, Nicholas J, Kantoff, Philip W, McLeod, David G, Pieczonka, Christopher M, Penson, David F, Shore, Neal D, Vacirca, Jeffrey, Concepcion, Raoul S, Tutrone, Ronald F, Nordquist, Luke T, Quinn, David I, Kassabian, Vahan, Scholz, Mark C, Harmon, Matt, Tyler, Robert C, Chang, Nancy N, Tang, Hong, and Cooperberg, Matthew R

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Prostate Cancer, Urologic Diseases, Aging, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Humans, Male, Neoplasm Metastasis, Prospective Studies, Prostatic Neoplasms, Castration-Resistant, Registries, Tissue Extracts, immunotherapy, overall survival, prostate cancer, safety, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundThe large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).MethodsPROCEED enrolled patients with mCRPC receiving 3 biweekly sipuleucel-T infusions. Assessments included overall survival (OS), serious adverse events (SAEs), cerebrovascular events (CVEs), and anticancer interventions (ACIs). Follow-up was for ≥3 years or until death or study withdrawal.ResultsIn 2011-2017, 1976 patients were followed for 46.6 months (median). The median age was 72 years, and the baseline median prostate-specific antigen level was 15.0 ng/mL; 86.7% were white, and 11.6% were African American. Among the patients, 1902 had 1 or more sipuleucel-T infusions. The median OS was 30.7 months (95% confidence interval [CI], 28.6-32.2 months). Known prognostic factors were independently associated with OS in a multivariable analysis. Among the 1255 patients who died, 964 (76.8%) died of prostate cancer (PC) progression. The median time from the first infusion to PC death was 42.7 months (95% CI, 39.4-46.2 months). The incidence of sipuleucel-T-related SAEs was 3.9%. The incidence of CVEs was 2.8%, and the rate per 100 person-years was 1.2 (95% CI, 0.9-1.6). The CVE incidence among 11,972 patients with mCRPC from the Surveillance, Epidemiology, and End Results-Medicare database was 2.8%; the rate per 100 person-years was 1.5 (95% CI, 1.4-1.7). One or more ACIs (abiraterone, enzalutamide, docetaxel, cabazitaxel, or radium 223) were received by 77.1% of the patients after sipuleucel-T; 32.5% and 17.4% of the patients experienced 1- and 2-year treatment-free intervals, respectively.ConclusionsPROCEED provides contemporary survival data for sipuleucel-T-treated men in a real-world setting of new life-prolonging agents, which will be useful in discussing treatment options with patients and in powering future trials with sipuleucel-T. The safety and tolerability of sipuleucel-T in PROCEED were consistent with previous findings.

Published
2019

33. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher J., Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ross, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Dan, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara A., Jones, Rob, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raja, Logothetis, Christopher, Mahal, Brandon, Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O’Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel J., Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark A., Ryan, Charles J., Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Published
2023
Full Text
View/download PDF

34. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher, Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ngozi Ekeke, Onyeanunam, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Daniel, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara Alicja, Jones, Robert, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raya, Logothetis, Christopher J., Mahal, Brandon A., Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark. A., Ryan, Charles J., Saad, Fred, Pablo Sade, Juan, Sartor, Oliver A., Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Published
2023
Full Text
View/download PDF

35. Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry

Author

Patierno, Brendon M., Foo, Wen-Chi, Allen, Tyler, Somarelli, Jason A., Ware, Kathryn E., Gupta, Santosh, Wise, Sandra, Wise, Sr., John P., Qin, Xiaodi, Zhang, Dadong, Xu, Lingfan, Li, Yanjing, Chen, Xufeng, Inman, Brant A., McCall, Shannon J., Huang, Jiaoti, Kittles, Rick A., Owzar, Kouros, Gregory, Simon, Armstrong, Andrew J., George, Daniel J., Patierno, Steven R., Hsu, David S., and Freedman, Jennifer A.

Published
2022
Full Text
View/download PDF

36. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer

Author

Koshkin, Vadim S., Patel, Vaibhav G., Ali, Alicia, Bilen, Mehmet A., Ravindranathan, Deepak, Park, Joseph J., Kellezi, Olesia, Cieslik, Marcin, Shaya, Justin, Cabal, Angelo, Brown, Landon, Labriola, Matthew, Graham, Laura S., Pritchard, Colin, Tripathi, Abhishek, Nusrat, Sanober, Barata, Pedro, Jang, Albert, Chen, Shuang R., Garje, Rohan, Acharya, Luna, Hwang, Clara, Pilling, Amanda, Oh, William, Jun, Tomi, Natesan, Divya, Nguyen, Chris, Kilari, Deepak, Pierro, Michael, Thapa, Bicky, Cackowski, Frank, Mack, Alleda, Heath, Elisabeth, Marshall, Catherine H., Tagawa, Scott T., Halabi, Susan, Schweizer, Michael T., Armstrong, Andrew, Dorff, Tanya, Alva, Ajjai, and McKay, Rana

Published
2022
Full Text
View/download PDF

38. Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).

Author

Chi, Kim N., primary, Agarwal, Neeraj, additional, Armstrong, Andrew J., additional, Hellmis, Eva, additional, Schlürmann, Friederike, additional, Sugimoto, Mikio, additional, Ürün, Yüksel, additional, Xing, Nianzeng, additional, Aregay, Mehreteab, additional, Lima, Julianne, additional, Meulendijks, Didier, additional, and Azad, Arun, additional

Published
2024
Full Text
View/download PDF

39. Association of tumor genetics with outcomes in patients (pts) with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617.

Author

Panian, Justine, primary, Henderson, Nicholas, additional, Barata, Pedro C., additional, Bilen, Mehmet Asim, additional, Graham, Laura, additional, Heath, Elisabeth I., additional, Herchenhorn, Daniel, additional, Hwang, Clara, additional, Kilari, Deepak, additional, Koshkin, Vadim S, additional, Nauseef, Jones T., additional, Sokolova, Alexandra, additional, Zakharia, Yousef, additional, Schweizer, Michael Thomas, additional, Dorff, Tanya B., additional, Armstrong, Andrew J., additional, Alva, Ajjai Shivaram, additional, and McKay, Rana R., additional

Published
2024
Full Text
View/download PDF

40. Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS.

Author

Morgans, Alicia K., primary, Sweeney, Christopher, additional, Wallis, Christopher J.D., additional, Halabi, Susan, additional, Armstrong, Andrew J., additional, Adorjan, Patrick, additional, Ghadessi, Mercedeh, additional, Verholen, Frank, additional, and Grimm, Marc-Oliver, additional

Published
2024
Full Text
View/download PDF

41. Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).

Author

George, Daniel J., primary, Halabi, Susan, additional, Fleming, Mark T., additional, Heath, Elisabeth I., additional, Tutrone, Ronald, additional, Sutton, Linda, additional, Whang, Young E., additional, Lewis, Brian E., additional, Humeniuk, Michael Sandon, additional, Harrison, Michael Roger, additional, Kephart, Julie, additional, Hurrelbrink, Julia, additional, Rasmussen, Julia, additional, Shobe, Kellie, additional, Anand, Monika, additional, Reyes-Martinez, Marco, additional, Howard, Lauren, additional, Patierno, Steven R., additional, Freedman, Jennifer A, additional, and Armstrong, Andrew J., additional

Published
2024
Full Text
View/download PDF

43. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond

Author

Zhu, Jason, Armstrong, Andrew J, Friedlander, Terence W, Kim, Won, Pal, Sumanta K, George, Daniel J, and Zhang, Tian

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Kidney Disease, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Biomarkers, Tumor, Carcinoma, Renal Cell, Humans, Immunotherapy, Kidney Neoplasms, Mutation, Programmed Cell Death 1 Receptor, Tumor Burden, Urinary Bladder Neoplasms, PD-L1, Biomarkers, Immune checkpoint inhibition, Urothelial carcinoma, Renal cell carcinoma, Oncology and carcinogenesis
Abstract

Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, response rates are low, and biomarkers are needed to predict for treatment response. Immunohistochemical quantification of PD-L1 was developed as a promising biomarker in early clinical trials, but many shortcomings of the four different assays (different antibodies, disparate cellular populations, and different thresholds of positivity) have limited its clinical utility. Further limitations include the use of archival specimens to measure this dynamic biomarker. Indeed, until PD-L1 testing is standardized and can consistently predict treatment outcome, the currently available PD-L1 assays are not clinically useful in urothelial and renal cell carcinoma. Other more promising biomarkers include tumor mutational burden, profiles of tumor infiltrating lymphocytes, molecular subtypes, and PD-L2. Potentially, a composite biomarker may be best but will need prospective testing to validate such a biomarker.

Published
2018

45. Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis

Author

Bu, Jiyoon, Jeong, Woo-jin, Jafari, Roya, Kubiatowicz, Luke J., Nair, Ashita, Poellmann, Michael J., Hong, Rachel S., Liu, Elizabeth W., Owen, Randall H., Rawding, Piper A., Hopkins, Caroline M., Kim, DaWon, George, Daniel J., Armstrong, Andrew J., Král, Petr, Wang, Andrew Z., Bruce, Justine, Zhang, Tian, Kimple, Randall J., and Hong, Seungpyo

Published
2022
Full Text
View/download PDF

48. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Gillessen, Silke, Armstrong, Andrew, Attard, Gert, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Robert G., Bulbul, Muhammad, Caffo, Orazio, Chi, Kim N., Clarke, Caroline S., Clarke, Noel, Davis, Ian D., de Bono, Johann S., Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fizazi, Karim, Frydenberg, Mark, George, Dan, Gleave, Martin, Halabi, Susan, Heinrich, Daniel, Higano, Celesta, Hofman, Michael S., Hussain, Maha, James, Nick, Jones, Robert, Kanesvaran, Ravindran, Khauli, Raja B., Klotz, Laurence, Leibowitz, Raya, Logothetis, Chris, Maluf, Fernando, Millman, Robin, Morgans, Alicia K., Morris, Michael J., Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G., Murthy, Vedang, Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Parker, Chris, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Rob E., Rubin, Mark, Ryan, Charles J., Saad, Fred, Sade, Juan P., Sartor, Oliver, Scher, Howard I., Shore, Neal, Skoneczna, Iwona, Small, Eric, Smith, Matthew, Soule, Howard, Spratt, Daniel E., Sternberg, Cora N., Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Tombal, Bertrand, Türkeri, Levent, Uemura, Hiroji, Uemura, Hirotsugu, van Oort, Inge, Yamoah, Kosj, Ye, Dingwei, Zapatero, Almudena, and Omlin, Aurelius

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results